DCI Research

In May, a phased-in process of reopening labs began, and by June 15 most labs were functioning at least on a partial basis.

On June 9, DCI and Susan G. Komen Triangle to Coast hosted "Navigating Survivorship,"a live patient forum on breast cancer and survivorship.

The Donald Lab, led by Bruce Donald, PhD, is designing proteins for a historically undruggable protein that’s implicated in difficult-to-treat cancers like pancreatic cancer.

Lyerly, Hartman spinout company Replicate Bioscience and Immunomic Therapeutics form collaboration to combat infectious diseases and cancers.

The Duke Cancer Institute Virtual Grand Rounds Series, came to a successful summer close with its final session on June 19.

Funding from the Elsa U. Pardee Foundation will allow investigator to study muscle regeneration and cancer.

Immunology expert Allan Kirk, MD, PhD, discusses what compels the immune system to respond to danger, and how our immune systems change over time.

Scott Soderling, PhD, has founded a Duke spinout company based on a technology developed in his lab that uses the genome-editing tool CRISPR.

 Yvonne Mowery, MD, PhD, was one of four young physician-scientists nationwide selected to receive the Damon Runyon Clinical Investigator Award.

Radiation oncologist Junzo Chino, MD, served as vice chair of the task force releasing recommendations for radiation therapy in nonmetastatic cervical cancer.

The authors, including corresponding author Madan Kwatra, MD, report that osimertinib inhibits the constitutive activity of EGFRv III tyrosine kinase with high potency.

Duke Cancer Institute will present more than 100 abstracts across multiple cancer types during the ASCO20 Virtual Scientific Program of the 2020 ASCO Annual Meeting.

Duke Cancer Institute's Michael Spiritos, MD, Meenal Kheterpal, MD, Momen Wahidi, MD, MBA, and Mustafa Bashir, MD, awarded 2020 DIHI Innovation Project Grants.

Duke Cancer Institute member and family physician Kevin Oeffinger, MD, has been named a Fellow of the American Society of Clinical Oncology (FASCO). 

Medical oncologist John Strickler, MD, and his patient Tom Vibert, a stage 4 colon cancer survivor, talk about the importance of biomarker testing.

Kyle Strickland, MD, PhD, received a Foundation for Women’s Cancer grant for research on endometrial cancer.

The CHDI at Duke Pediatrics hosts DCI molecular biologist Jason Somarelli, PhD, for a virtual talk on cancer therapy resistance on May 5 at 1 p.m.

The research team found a signaling pathway within melanoma and other cancers that thwart the functioning of anti-PD-1 checkpoint inhibitors.

Duke University School of Medicine podcast "HeadScratchers" features Kelly Marcom, MD.

Christopher Kelsey, MD, associate professor in the Department of Radiation Oncology and DCI member, was awarded the 2020 Algernon Sydney Sullivan Award.

Nia Mitchell, MD, MPH, will presents: "Developing a Framework for Integrating Take Off Pounds Sensibly (TOPS) into Community Health Centers."

Kris Wood, PhD, and team, are investigating how to turn a tumor’s strength – its drug resistance – into a weakness. This research was published in Nature Genetics.

If mothers, sisters and daughters have a history of breast and ovarian cancers, a man's risk for prostate cancer is also significantly increased.

Yousuf Zafar, MD, MHS, FASCO, was honored to deliver the keynote for this year's ASCO Gastrointestinal Cancers Symposium.

Graduate program rankings released today by U.S. News & World Report place the School of Nursing and School of Medicine among the top in the nation.

Lifetime Achievement Award Winner Keith Sullivan, MD, and colleagues reflect on his career and passion.

Thomas A. D’Amico, MD, chair, NCCN Quality and Outcomes Cmte: "These 22 measures represent a feasible standard for documenting quality improvement in cancer care."

A new Bone Metastasis Clinic focuses exclusively on patients like Pam Kohl whose cancer has spread to their arms, legs or pelvis.
 

Duke and Leica formally established a Leica Microsystems Center of Excellence at the Light Microscopy Shared Resource.

Mentored-research training award boosts the next generation of Duke physician-scientists.

Duke researchers are using a $200,000 grant from NC Biotech to “supercharge” vital medical information.

The Duke Department of Pathology/Duke Clinical Labs has established the Division of Artificial Intelligence and Computational Pathology.

Duke University ranked eighth among the nation’s top medical schools and research institutions for funding from the NIH.

Research on immunotherapy in NSCLC by Scott Antonia, MD, PhD, selected by ASCO for inclusion in Clinical Cancer Advances 2020.

DCI researchers use the modified polio virus to spur natural immune attack against tumors in animal studies.

Dorothy Sipkins, MD, PhD, and P. Kelly Marcom, MD, are co-PIs on a Phase 1 clinical trial of a new drug for breast cancer patients whose disease has spread to the bone.

Lawrence A. David, PhD, and Anthony D. Sung, MD, named recipients of the Damon Runyon-Rachleff Innovation Award for project to personalize pre-biotic treatments for HCT patients.

This year's Annual Report spotlights the work of the new Duke Center for Brain and Spine Metastasis at DCI as well as a Duke-Durham stomach cancer prevention partnership. 

For Preston Robert Tisch Brain Tumor Center staff assistant Anne Beebe, the center's annual Angels Among Us 5K and Walk of Hope is deeply personal.

Medical oncologist Edwin P. Alyea, III, MD, formerly with Dana-Farber Cancer Institute, has been named chief medical officer (CMO) for Duke Cancer Institute.

Mark Oldham, PhD, has been named director of the Medical Physics Program, effective January 1, 2020.

In a new Cell Reports paper, DCI researchers report they've uncovered actionable targets for the treatment of brain metastases harboring lung adenocarcinoma.

David Bartlett, PhD, has been selected to receive an ASH Scholar Award to study impact of exercize training on CLL.

DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.

Jennifer K. Plichta, MD, Assistant Professor of Surgery, Division of Surgical Oncology, on being appointed to the editorial board of Breast Cancer Research.

April Salama, MD, director of the Melanoma Disease Group, has joined the Duke Center for Brain and Spine Metastasis at DCI as associate medical director.

Lola Fayanju, MD, and her team will develop a prediction model to identify women with mutable risk factors for compromised breast cancer care.

Drug tested in lab studies halts cancer cells that are impervious to hormone therapy.

DCI member Kathryn R Nightingale, PhD, was recently elected Fellow of the National Academy of Inventors.

DCI researchers have observed how stem cell mutations quietly arise and spread throughout a widening field of the colon until they eventually predominate and become a malignancy.